NCT05545319

Simple Title
AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED NIRMATRELVIR/RITONAVIR COMPARED WITH PLACEBO/RITONAVIR FOR THE TREATMENT OF SEVERE COVID-19 IN HOSPITALIZED PARTICIPANTS WHO ARE IMMUNOCOMPROMISED OR AT INCREASED RISK FOR SEVERE COVID-19 OUTCOMES

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Who may participate

Each clinical study has its own guidelines for who may participate, called eligibility criteria. These factors can include your age, sex, overall health, type and stage of disease, and personal treatment history. However, only the research study staff can determine if you qualify to enroll in the study.

Condition

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), Immunocompromised, Hospitalization, Child, Hospitalized

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.
Sex
Male or Female
The sex of people who may participate in a clinical trial (all, female, male). Sex is a person’s classification based on assignment at birth. Eligibility based on sex is distinct from eligibility based on gender.
Age
12+ years
The age a person must be to participate in a clinical trial.
View more eligibility criteria on ClinicalTrials.gov

Study Locations

Study Locations
1 trials found.

Harlem Hospital Center

New York, New York, United States, 10037